蛋白酪氨酸激酶信号转导途径与抗肿瘤药物

被引：42

作者：

茆勇军 ^{[1
]}

李海泓 ^{[2
]}

李剑峰 ^{[1
]}

沈敬山 ^{[1
]}

机构：

[1] 中国科学院上海药物研究所

[2] 上海特化医药科技有限公司

来源：

药学学报 | 2008年 / 04期

关键词：

信号转导; 受体酪氨酸激酶; 非受体酪氨酸激酶; 酪氨酸激酶抑制剂; 抗肿瘤药物;

D O I：

10.16438/j.0513-4870.2008.04.011

中图分类号：

R979.1 [抗肿瘤、抗癌药物];

学科分类号：

1007 ;

摘要：

细胞信号转导(signal transduction)在细胞的代谢、分裂、分化、生物功能及死亡过程中起着重要作用,肿瘤的发生和发展与细胞信号转导过度激活有关。本文简要阐述了蛋白酪氨酸激酶(prote in tyrosine k inases,PTKs)介导的信号转导途径,分别介绍了受体酪氨酸激酶介导的Ras/Raf/MAPK和PI-3K/Akt途径,非受体酪氨酸激酶介导的Src、Bcr-Ab l和JAK/STAT途径。以此5条信号转导通路中参与的重要蛋白分子为靶点,统计和介绍了相关的已经上市或处于临床研究的抗肿瘤药物。

引用

页码：323 / 334

页数：12

共 8 条

[1]

Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future[J] . MacKenzie,von Mehren.Expert Review of Anticancer Therapy . 2007 (8)

[2] Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma [J].

Reuter, Christoph W. M. ;

Morgan, Michael A. ;

Gruenwald, Viktor ;

Herrmann, Thomas R. W. ;

Burchardt, Martin ;

Ganser, Arnold .

WORLD JOURNAL OF UROLOGY, 2007, 25 (01) :59-72

[3]

Beyond Imatinib: Second Generation c-KIT Inhibitors for the Management of Gastrointestinal Stromal Tumors[J] . Margaret von Mehren.Clinical Colorectal Cancer . 2006

[4] Targeting the ERK signaling pathway in cancer therapy [J].

Kohno, M ;

Pouyssegur, J .

ANNALS OF MEDICINE, 2006, 38 (03) :200-211

[5]

Inhibition of Vascular Endothelial Growth Factor （VEGF） Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts[J] . Tetsuichiro Inai,Michael Mancuso,Hiroya Hashizume,Fabienne Baffert,Amy Haskell,Peter Baluk,Dana D. Hu-Lowe,David R. Shalinsky,Gavin Thurston,George D. Yancopoulos,Donald M. McDonald.The American Journal of Pathology . 2004 (1)

[6]

Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity[J] . Claus Liebmann.Cellular Signalling . 2001 (11)

[7]

Tyrosinekinasereceptor-mediatedsignaltransductionandcancertreatment. ZhuXF,LiuZC,ZengYX. 药学学报 . 2002

[8]

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification. Mercedes E. Gorre,Mansoor Mohammed,Katharine Ellwood,Nicholas Hsu,Ron Paquette,P. Nagesh Rao,Charles L. Sawyers. Science . 2001

← 1 →